$1.03
0.03 (+2.99%)
StemCells, Inc. (NASDAQ:STEM)
CAPS Rating:
A biopharmaceutical company that operates in one segment, the development of novel cell-based therapeutics designed to treat human diseases and disorders.
A biopharmaceutical company that operates in one segment, the development of novel cell-based therapeutics designed to treat human diseases and disorders.